Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy ; volume:7 ; number:1 ; day:17 ; month:10 ; year:2017 ; pages:1-13 ; date:12.2017
Scientific reports ; 7, Heft 1 (17.10.2017), 1-13, 12.2017
- Urheber
-
Nejadmoghaddam, Mohammad-Reza
Zarnani, Amir-Hassan
Ghahremanzadeh, Ramin
Ghods, Roya
Mahmoudian, Jafar
Yousefi, Maryam
Nazari, Mahboobeh
Ghahremani, Mohammad Hossein
Abolhasani, Maryam
Anissian, Ali
Mahmoudi, Morteza
Dinarvand, Rassoul
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-017-13682-9
- URN
-
urn:nbn:de:101:1-2019102019501986166133
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:35 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Nejadmoghaddam, Mohammad-Reza
- Zarnani, Amir-Hassan
- Ghahremanzadeh, Ramin
- Ghods, Roya
- Mahmoudian, Jafar
- Yousefi, Maryam
- Nazari, Mahboobeh
- Ghahremani, Mohammad Hossein
- Abolhasani, Maryam
- Anissian, Ali
- Mahmoudi, Morteza
- Dinarvand, Rassoul
- SpringerLink (Online service)
Ähnliche Objekte (12)
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein
Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate
The First FDA-Approved Antibody-Drug Conjugate
Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate
Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy
An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers
Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates
HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma
Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates
Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein